Treatment

Latest guidelines on anti-CGRP antibodies: first-line and long-term use 2:24
Latest guidelines on anti-CGRP antibodies: first-line and long-term use
Messoud Ashina • 23 Jun 2022
Long-term efficacy of adjunctive cenobamate in patients with focal seizures 1:39
Long-term efficacy of adjunctive cenobamate in patients with focal seizures
Christian Brandt • 14 Jun 2022
Progressive MS treatment – what is next? 1:39
Progressive MS treatment – what is next?
Giancarlo Comi • 23 Mar 2022
A personalized approach for neurostimulation 1:32
A personalized approach for neurostimulation
Roi Cohen Kadosh • 23 Mar 2022
Methods for measuring treatment response and disease progression in MS 6:51
Methods for measuring treatment response and disease progression in MS
Giancarlo Comi • 23 Mar 2022
Neurostimulation to improve cognition in health and disease 3:58
Neurostimulation to improve cognition in health and disease
Roi Cohen Kadosh • 23 Mar 2022
The future of patient-reported outcomes in progressive MS 1:47
The future of patient-reported outcomes in progressive MS
Giancarlo Comi • 23 Mar 2022
Future directions of neurostimulation 2:03
Future directions of neurostimulation
Roi Cohen Kadosh • 23 Mar 2022
Improving brain waste clearance to treat CAA and Alzheimer’s disease 3:14
Improving brain waste clearance to treat CAA and Alzheimer’s disease
Roxana Carare • 4 May 2022
Unresolved questions on post-stroke anticoagulation in atrial fibrillation 8:00
Unresolved questions on post-stroke anticoagulation in atrial fibrillation
Nils Peters et al. • 4 May 2022
ATTICUS trial of apixaban vs aspirin for secondary prevention after ESUS: findings & implications 22:22
ATTICUS trial of apixaban vs aspirin for secondary prevention after ESUS: findings & implications
Sven Poli et al. • 20 May 2022
Blood-brain barrier disruption increases the risk of hemorrhagic transformation in ischemic stroke 1:19
Blood-brain barrier disruption increases the risk of hemorrhagic transformation in ischemic stroke
Francesco Arba • 4 May 2022
Does bridging thrombolysis impact clot composition? 1:52
Does bridging thrombolysis impact clot composition?
Rosanna Rossi • 5 May 2022
The value of specific reversal agents in stroke management 5:59
The value of specific reversal agents in stroke management
Senta Frol • 17 May 2022
Using DMTs beyond patients with active MS 3:14
Using DMTs beyond patients with active MS
Xavier Montalban • 29 Mar 2022
The clinical benefit of safinamide in treating Parkinson’s disease 1:46
The clinical benefit of safinamide in treating Parkinson’s disease
Angelo Antonini • 29 Mar 2022
The content of VJNeurology is intended for healthcare professionals